Literature DB >> 8906994

Cupric and ferric ions inactivate HIV.

J L Sagripanti1, M M Lightfoote.   

Abstract

Human immunodeficiency virus (HIV-1) was inactivated by either cupric or ferric ions when the virus was free in solution and also 3 hr after cell infection. Fifty percent inactivation of cell-free HIV was achieved with Cu(II) at a concentration between 0.16 and 1.6 mM, or by 1.8 to 18 mM Fe(III). Thus, the dose to inactivate 50% of infectious HIV (D50) by Cu(II) or Fe(III) is higher than that reported for glutaraldehyde (0.1 mM); between the D50 reported for sodium hypochlorite (1.3 mM) and sodium hydroxide (11.5 mM), and significantly lower than that required for HIV inactivation by ethanol (360 mM). Treatment of infected cells for 30 min at 20 degrees C with 6 mM Cu(II) or Fe(III) completely inhibited the formation of syncytia and the synthesis of virus-specific p24 antigen in HIV-infected cells, while still preserving cell viability. The virucidal properties of cupric and ferric ions could be exploited for the development of novel virucidal formulations efficient against HIV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906994     DOI: 10.1089/aid.1996.12.333

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  13 in total

1.  Novel antiviral characteristics of nanosized copper(I) iodide particles showing inactivation activity against 2009 pandemic H1N1 influenza virus.

Authors:  Yoshie Fujimori; Tetsuya Sato; Taishi Hayata; Tomokazu Nagao; Mikio Nakayama; Tsuruo Nakayama; Ryuichi Sugamata; Kazuo Suzuki
Journal:  Appl Environ Microbiol       Date:  2011-12-09       Impact factor: 4.792

Review 2.  The Use of Copper as an Antimicrobial Agent in Health Care, Including Obstetrics and Gynecology.

Authors:  Linda P Arendsen; Ranee Thakar; Abdul H Sultan
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

3.  Mechanism of copper-mediated inactivation of herpes simplex virus.

Authors:  J L Sagripanti; L B Routson; A C Bonifacino; C D Lytle
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 4.  Exploring the Role of Heavy Metals and Their Derivatives on the Pathophysiology of COVID-19.

Authors:  Ali Bahrami; Mohammad Reza Arabestani; Mohammad Taheri; Abbas Farmany; Fatemeh Norozzadeh; Seyed Mostafa Hosseini; Hesam Nozari; Fatemeh Nouri
Journal:  Biol Trace Elem Res       Date:  2021-08-27       Impact factor: 4.081

5.  A novel anti-influenza copper oxide containing respiratory face mask.

Authors:  Gadi Borkow; Steve S Zhou; Tom Page; Jeffrey Gabbay
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

6.  Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters.

Authors:  Gadi Borkow; Humberto H Lara; Chandice Y Covington; Adeline Nyamathi; Jeffrey Gabbay
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Evaluation of pigtail macaques as a model for the effects of copper intrauterine devices on HIV infection.

Authors:  Robyn M Engel; Monica Morris; Tara Henning; Jana M Ritter; Tara L Jones; Sharon Dietz; Jessica Ayers; Sundaram A Vishwanathan; Leecresia Jenkins; Sherif Zaki; Dirk Wildemeersch; David Garber; Nathaniel Powell; R Michael Hendry; Janet McNicholl; Ellen N Kersh
Journal:  J Med Primatol       Date:  2013-12-27       Impact factor: 0.667

8.  In vitro antiretroviral activity and in vivo toxicity of the potential topical microbicide copper phthalocyanine sulfate.

Authors:  Ashley R Styczynski; Khandaker N Anwar; Habiba Sultana; Abdelhamid Ghanem; Nell Lurain; Aishi Chua; Mahmood Ghassemi; Richard M Novak
Journal:  Virol J       Date:  2015-08-30       Impact factor: 4.099

9.  The physiology and pharmacology of singlet oxygen.

Authors:  Thomas W Stief
Journal:  Med Hypotheses       Date:  2003-04       Impact factor: 1.538

10.  MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro.

Authors:  Mamdooh Ghoneum; Magda Shaheen
Journal:  Evid Based Complement Alternat Med       Date:  2008-03-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.